Clene Inc. is offering 1,219,513 common shares at $3.28 each, expecting approximately $4.0 million in proceeds before expenses. The funds are intended for general corporate purposes, including regulatory dialogue, filings and a new drug application for CNM-Au8, plus expanded access, potential commercialization and Manufacturing expansion.
Key Highlights
- Certain Clene directors and officers have agreed to buy shares worth approximately $2.1 million.
- Shares outstanding immediately after the offering are expected to total 14,213,981.
- Clene Inc. is offering 1,219,513 shares of common stock.
Clene Inc. (NASDAQ: CLNN) is offering 1,219,513 shares of common stock at $3.28 per share, targeting approximately $4.0 million in proceeds before expenses. The funds are intended for general corporate purposes, including regulatory work and preparation of a new drug application for CNM-Au8.
Insider Participation and Share Count
Certain directors and officers have agreed to purchase approximately $2.1 million of the stock at the offering price. The shares carry a Par Value of $0.0001 per share. Clene expects 14,213,981 common shares to be outstanding immediately after the transaction, based on 12,994,468 shares outstanding as of September 14, 2026. Delivery of the shares is expected on or about September 16, 2026.
FAQs
Q: How many shares is Clene Inc. offering?
A: Clene Inc. is offering 1,219,513 shares of common stock. The offering price is $3.28 per share, with approximately $4.0 million in proceeds expected before expenses.
Q: How much are Clene directors and officers purchasing?
A: Certain Clene directors and officers have agreed to purchase shares with an aggregate price of approximately $2.1 million. They will buy at the offering price.
Q: What will Clene use the stock offering proceeds for?
A: Clene plans to use net proceeds and existing cash for regulatory dialogue, filings and a new drug application for CNM-Au8. Potential commercialization efforts and manufacturing expansion are also included.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.